Back to results
US 2013/0096068 A1Published application
Combination therapy with a proteasome inhibitor and a gallium complex
AssigneeNiiki Pharma Inc.
InventorHooshmand SHESHBARADARAN
Life of this patent
Estimating the term…
Abstract
A combination therapy is disclosed for treating cancer. The method comprises identifying a patient diagnosed of cancer and in need of treatment, administering to a cancer patient a therapeutically effective amount of a compound of Formula (I), and administering to said patient a therapeutically effective amount of a proteasome inhibitor.
Claims15
A method of treating proliferative disorder, comprising
- administering, simultaneously or sequentially, to a patient in need of the treatment a therapeutically effective amount of a compound of Formula (I)
- wherein R1 represents hydrogen, a halogen or a sulfono group SO3M, in which M is a metal ion, and R2 represents hydrogen, or R1 is Cl and R2 is I, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proteasome inhibitor.
A kit, comprising in a compartmentalized container:
- a first unit dosage form having a compound of Formula (I)
- wherein R1 represents hydrogen, a halogen or a sulfono group SO3M, in which M is a metal ion, and R2 represents hydrogen, or R1 is Cl and R2 is I, or a pharmaceutically acceptable salt thereof;
- and
- a second unit dosage form having a proteasome inhibitor.
1 more element
A pharmaceutical composition, comprising a therapeutically effective amount of a compound of Formula (I)
- wherein R1 represents hydrogen, a halogen or a sulfono group SO3M, in which M is a metal ion, and R2 represents hydrogen, or R1 is Cl and R2 is I, or a pharmaceutically acceptable salt thereof and a proteasome inhibitor.
Dependencies are inferred from the claim text.